Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$0.78 -2.1%	$1.13	$0.74 ▼ $1.76	$31.22M	1.09	687,430 shs	200,792 shs
AXLA Axcella Health	$0.40 -8.9%	$0.84	$0.34 ▼ $41.25	$1.18M	0.46	267,009 shs	6,700 shs
BCDA BioCardia	$0.36 -4.5%	$0.42	$0.36 ▼ $2.92	$9.67M	1.47	334,420 shs	97,107 shs
OKYO OKYO Pharma	$1.40 -4.3%	$1.45	$0.92 ▼ $3.25	$40.44M	0.04	159,878 shs	13,243 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	-2.91%	-5.88%	-32.77%	-2.76%	-11.01%
AXLA Axcella Health	0.00%	0.00%	0.00%	0.00%	-96.17%
BCDA BioCardia	+2.42%	-1.62%	-1.36%	-13.73%	-81.15%
OKYO OKYO Pharma	+4.26%	+10.53%	-0.34%	-9.26%	+17.60%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHL Achilles Therapeutics	1.8858 of 5 stars	3.0	3.0	0.0	0.0	2.5	0.8	1.3
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BCDA BioCardia	1.7015 of 5 stars	3.3	5.0	0.0	0.0	0.0	2.5	0.0
OKYO OKYO Pharma	1.6026 of 5 stars	3.5	3.0	0.0	0.0	0.6	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHL Achilles Therapeutics	2.00	Hold	$4.00	410.92% Upside
AXLA Axcella Health	N/A	N/A	N/A	N/A
BCDA BioCardia	2.50	Moderate Buy	$4.00	1,011.11% Upside
OKYO OKYO Pharma	3.00	Buy	$7.00	399.04% Upside

Current Analyst Ratings

Latest AXLA, OKYO, ACHL, and BCDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/5/2024	ACHL Achilles Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $6.00
4/5/2024	ACHL Achilles Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$8.00 ➝ $2.00
3/22/2024	OKYO OKYO Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.49 per share	N/A
AXLA Axcella Health	N/A	N/A	N/A	N/A	$1.42 per share	N/A
BCDA BioCardia	$480K	20.15	N/A	N/A	($0.07) per share	-5.14
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.08) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHL Achilles Therapeutics	-$69.67M	-$1.74	N/A	N/A	N/A	N/A	-42.55%	-37.54%	5/8/2024 (Estimated)
AXLA Axcella Health	-$81.19M	-$19.25	N/A	∞	N/A	N/A	N/A	-259.91%	N/A
BCDA BioCardia	-$11.57M	-$0.55	N/A	N/A	N/A	-2,425.79%	-3,638.68%	-228.55%	5/8/2024 (Estimated)
OKYO OKYO Pharma	-$13.27M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/20/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHL Achilles Therapeutics	N/A	8.57	8.57
AXLA Axcella Health	N/A	0.80	0.80
BCDA BioCardia	N/A	0.40	0.40
OKYO OKYO Pharma	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ACHL Achilles Therapeutics	56.38%
AXLA Axcella Health	65.07%
BCDA BioCardia	20.57%
OKYO OKYO Pharma	2.97%

Insider Ownership

Company	Insider Ownership
ACHL Achilles Therapeutics	5.38%
AXLA Axcella Health	2.20%
BCDA BioCardia	23.90%
OKYO OKYO Pharma	40.46%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHL Achilles Therapeutics	204	39.88 million	37.73 million	Not Optionable
AXLA Axcella Health	11	2.95 million	2.88 million	Optionable
BCDA BioCardia	16	26.87 million	20.45 million	Optionable
OKYO OKYO Pharma	8	28.83 million	17.17 million	Not Optionable

AXLA, OKYO, ACHL, and BCDA Headlines

Source	Headline
	OKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader event proactiveinvestors.com - April 9 at 8:39 AM
	OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 globenewswire.com - April 8 at 7:00 PM
$OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery$	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery globenewswire.com - April 2 at 7:00 AM
	Japan authorities inspect second Kobayashi Pharma factory after deaths msn.com - March 31 at 9:46 PM
	Japan dietary supplement maker probes five deaths msn.com - March 29 at 8:56 AM
	Analysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB) markets.businessinsider.com - March 27 at 6:32 PM
	OKYO Pharma gains after positive results from Phase 2 dry eye disease trial msn.com - March 22 at 3:14 PM
	Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study msn.com - March 22 at 3:14 PM
	OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms proactiveinvestors.com - March 22 at 8:52 AM
	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 globenewswire.com - March 22 at 7:00 AM
	OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye disease proactiveinvestors.com - March 21 at 9:23 AM
	OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial globenewswire.com - March 21 at 7:00 AM
	OKYO Pharma to release Phase 2 dry eye disease trial results on Friday proactiveinvestors.com - March 20 at 8:55 AM
	OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event globenewswire.com - March 20 at 7:00 AM
	OKYO Pharma Limited (OKYO) Stock Price, News, Quote & History - Yahoo Finance finance.yahoo.com - March 19 at 11:17 AM
	Tokyo stocks open lower as gains locked in, BOJ outcome awaited msn.com - March 19 at 1:09 AM
	OKYO Pharma (OKYO) Price Target Increased by 20.00% to 6.12 msn.com - February 25 at 8:55 AM
	Tokyo stocks open flat as gains locked in, exporters rise msn.com - February 20 at 1:07 PM
	OKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trial proactiveinvestors.com - February 9 at 8:47 AM
	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain finance.yahoo.com - February 9 at 8:00 AM
	Pulling plug on Aduhelm in AD, Biogen turns resources to Leqembi bioworld.com - February 2 at 1:16 PM
	Stock market today: Asian shares mostly rise after Wall Street rebounds led by tech stocks msn.com - February 2 at 1:16 PM
	OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board finance.yahoo.com - January 31 at 8:20 AM
	Eagles files lawsuit in patent dispute over cancer therapy msn.com - January 18 at 9:32 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Achilles Therapeutics

NASDAQ:ACHL

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Axcella Health

NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

BioCardia

NASDAQ:BCDA

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

OKYO Pharma

NASDAQ:OKYO

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial